NLRP3 and cryopyrin-associated periodic syndrome: Notably, in 2015, the small-molecule inhibitor MCC950 (CRID3 or CP-456773) showcased potent and selective NLRP3 inhibition in several preclinical models and human samples from CAPS patients, providing an initial breakthrough (Coll et al, 2015).